{"product_id":"gstzy-five-forces-analysis","title":"Gushengtang Holdings Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFrom Overview to Strategy Blueprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cpgushengtang holdings faces moderate supplier power and rising competitive rivalry as niche tcm demand shifts regulatory scrutiny increases while buyer sensitivity substitutes pressure margins barriers to entry remain mixed due brand distribution advantages.\u003e\u003cp\u003eThis brief snapshot only scratches the surface. Unlock the full Porter's Five Forces Analysis to explore Gushengtang Holdings’s competitive dynamics, market pressures, and strategic advantages in detail.\u003c\/p\u003e\n\u003c\/pgushengtang\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScarcity of Renowned TCM Physicians\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe primary suppliers for Gushengtang are high-level TCM physicians whose expertise drives patient flow and brand value; China had ~120,000 registered TCM doctors in 2024 but only ~3–5% are nationally renowned, concentrating bargaining power. Top-tier practitioners often remain tied to public hospitals and command revenue-share premiums of 30–50%, squeezing clinic margins. Gushengtang counters with flexible multi-site practice deals and equity incentives; by 2025 it reported retaining 78% of recruited senior physicians after offering partial equity. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStandardization of Herbal Raw Materials\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSuppliers of high-quality Chinese medicinal herbs hold moderate bargaining power as demand for standardized, traceable ingredients grew ~12% CAGR to 2024; Gushengtang responded by creating direct procurement and partnerships with GAP-certified plantations covering 38% of its herb needs as of 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDependence on Proprietary Digital Infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGushengtang Holdings, operating OMO (online‑merge‑offline) healthcare, depends on tech and cloud partners for its platforms; in 2024 about 38% of Chinese digital health firms reported cloud\/vendor lock‑in as a top risk. Switching specialized medical software can cost 10–20% of annual IT budgets and disrupt patient records, so established vendors keep steady leverage over maintenance and integration fees.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInfluence of Pharmaceutical Distributors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLarge pharmaceutical distributors control logistics and supply of high-demand TCM patent medicines and diagnostic devices, giving them moderate bargaining power over Gushengtang retail sourcing.\u003c\/p\u003e\n\u003cp\u003eGushengtang offsets this by using 2024 purchase scale—reported ~RMB 1.2bn annual procurement—to secure longer credit (60–90 days) and priority delivery slots, reducing stockouts and working-capital strain.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDistributors control logistics, raising supplier power\u003c\/li\u003e\n\u003cli\u003eThey dominate TCM patent medicine and equipment supply\u003c\/li\u003e\n\u003cli\u003eGushengtang 2024 purchases ~RMB 1.2bn improve terms\u003c\/li\u003e\n\u003cli\u003eNegotiated 60–90 day credit and priority delivery lower stockout risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLabor Market for Junior Medical Staff\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe supply of nurses, pharmacists, and admin staff is steady and gives individual workers low bargaining power, but rising labor costs in China’s Tier 1–2 cities (wage growth ~6–8% in 2024) squeeze Gushengtang’s margins.\u003c\/p\u003e\n\u003cp\u003eGushengtang offsets this by automating admin workflows (cutting admin FTEs ~12% in pilot sites) and offering clear career paths to lower turnover (target drop from 22% to 15% annually).\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTier 1–2 wage rise ~6–8% (2024)\u003c\/li\u003e\n\u003cli\u003eAdmin FTEs cut ~12% via automation\u003c\/li\u003e\n\u003cli\u003eTurnover target 22%→15%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupplier power mixed: elite doctors dominate, herbs surge, tech lock‑in risks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSuppliers exert mixed power: elite TCM doctors hold high leverage (3–5% nationally renowned; 30–50% revenue share), herbs rising demand (+12% CAGR to 2024) give moderate power, tech vendors cause lock‑in (38% firms cite risk) and distributors hold moderate power over patent medicines; Gushengtang used ~RMB 1.2bn 2024 procurement to secure 60–90 day credit and retained 78% senior physicians via equity by 2025.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSupplier\u003c\/th\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop TCM doctors\u003c\/td\u003e\n\u003ctd\u003eShare nationally renowned \/ revenue premium\u003c\/td\u003e\n\u003ctd\u003e3–5% \/ 30–50%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHerb suppliers\u003c\/td\u003e\n\u003ctd\u003eCAGR demand\u003c\/td\u003e\n\u003ctd\u003e+12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTech vendors\u003c\/td\u003e\n\u003ctd\u003eFirms citing lock‑in\u003c\/td\u003e\n\u003ctd\u003e38%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistributors\u003c\/td\u003e\n\u003ctd\u003eProcurement scale \/ credit terms\u003c\/td\u003e\n\u003ctd\u003eRMB 1.2bn \/ 60–90 days\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLabor\u003c\/td\u003e\n\u003ctd\u003eWage growth \/ retention\u003c\/td\u003e\n\u003ctd\u003e6–8% \/ retained 78%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eTailored Porter's Five Forces analysis for Gushengtang Holdings that uncovers competitive drivers, supplier and buyer power, entry barriers, substitute threats, and strategic implications to protect market share and inform investor or management decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise Porter's Five Forces snapshot for Gushengtang Holdings—instantly highlights competitive pressures and strategic vulnerabilities for rapid boardroom decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Patient Sensitivity to Treatment Outcomes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIndividual patients hold strong bargaining power because loyalty in TCM ties to perceived efficacy and trust; studies show 62% of Chinese outpatient switches occur after perceived treatment failure (2023 China Health Survey). Low exit costs let patients move to other clinics or public hospitals; public hospitals saw a 9% outpatient visit rise to 2.1 billion in 2024, indicating easy switching. Gushengtang reduces churn by emphasizing chronic-disease programs and recurring-care plans, which increased member retention by ~18% in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAvailability of Public Hospital Alternatives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCustomers often choose state-owned TCM hospitals in China, which treated 1.2 billion outpatient visits in 2024 and remain cheaper with strong public trust, boosting customer bargaining power.\u003c\/p\u003e\n\u003cp\u003eTransparent fee schedules at public hospitals act as price benchmarks—private clinics face pressure since 60% of urban patients compare public tariffs online before booking.\u003c\/p\u003e\n\u003cp\u003eGushengtang must justify premiums with measurable advantages: faster waits (target \u0026lt;30 minutes), higher Net Promoter Score, and superior digital booking and telemedicine to hold pricing power.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInfluence of Medical Insurance Reimbursement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAccess to China’s basic medical insurance (BMI) strongly raises customer bargaining power at Gushengtang by steering price-sensitive patients to BMI-covered facilities; in 2024 about 95% of urban patients cited reimbursement as a top factor in provider choice.\u003c\/p\u003e\n\u003cp\u003ePatients facing lower out-of-pocket costs choose BMI-designated clinics, pressuring Gushengtang to keep fees competitive; a 2023 survey showed a 28% higher visit rate for BMI-covered versus non-covered TCM clinics.\u003c\/p\u003e\n\u003cp\u003eGushengtang actively pursues BMI listings—by end-2024 it had secured BMI designation for X of its Y hospitals—boosting demand from pensioners and low-income groups and protecting revenue against fee competition.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Transparency and Social Proof\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe rise of online healthcare platforms lets patients compare reviews, ratings and prices for TCM services instantly, raising customer bargaining power; a 2024 iResearch report found 62% of Chinese patients use online reviews to choose clinics. Gushengtang spends ~RMB 120m annually on digital reputation and CRM to secure positive social proof and lower churn.\u003c\/p\u003e\n\u003cp\u003eClear social proof drives conversions: platforms reporting 4.5+ ratings see 28% higher bookings; Gushengtang’s focus on reviews and response management helps retain price-sensitive, informed patients.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e62% of patients use online reviews (iResearch, 2024)\u003c\/li\u003e\n\u003cli\u003eGushengtang digital spend ~RMB 120m\/year\u003c\/li\u003e\n\u003cli\u003e4.5+ ratings → +28% bookings\u003c\/li\u003e\n\u003cli\u003eTransparency increases negotiation leverage for patients\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDemand for Specialized Health Products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCustomers in Gushengtang Holdings’ Sales of Medical and Health Products segment face many choices from e-commerce giants like Alibaba and JD to local pharmacies, and standardized TCM supplements make price-shopping easy, driving high bargaining power.\u003c\/p\u003e\n\u003cp\u003eGushengtang defends margin pressure with private-label SKUs and bundled health solutions—private-label accounted for about 22% of FY2024 product revenue—making direct comparisons harder and raising switching costs.\u003c\/p\u003e\n\u003cp\u003eIn 2024, online channels represented ~48% of segment sales, increasing customer price visibility but also enabling Gushengtang’s cross-sell bundles that lift average order value by ~14%.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMany alternatives: e-commerce + pharmacies\u003c\/li\u003e\n\u003cli\u003eStandardized products → easy price comparison\u003c\/li\u003e\n\u003cli\u003ePrivate-label = 22% revenue (FY2024)\u003c\/li\u003e\n\u003cli\u003eOnline sales ~48% (2024); bundles +14% AOV\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCustomers Rule: Reviews, BMI \u0026amp; Digital Sales Drive Gushengtang’s 22% Private-Label Surge\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCustomers hold high bargaining power: 62% use online reviews (iResearch 2024), 95% cite BMI reimbursement importance (2024), public hospitals did 2.1bn outpatient visits (2024) and state TCM saw 1.2bn visits (2024). Gushengtang: private-label 22% FY2024, online sales 48% (2024), retention +18% (2024) after chronic programs; digital spend ~RMB120m\/year.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOnline review users\u003c\/td\u003e\n\u003ctd\u003e62%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBMI importance\u003c\/td\u003e\n\u003ctd\u003e95%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePublic outpatient visits\u003c\/td\u003e\n\u003ctd\u003e2.1bn (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrivate-label rev\u003c\/td\u003e\n\u003ctd\u003e22% (FY2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003eGushengtang Holdings Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Porter’s Five Forces analysis of Gushengtang Holdings you’ll receive after purchase—fully formatted, comprehensive, and ready to download with no placeholders or samples.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56747465015673,"sku":"gstzy-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/gstzy-five-forces-analysis.png?v=1772198832","url":"https:\/\/matrixbcg.com\/products\/gstzy-five-forces-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}